Metagenomi, Inc.

Industry

  • Pharmaceuticals
  • Digital Health
    • Artificial Intelligence
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Drug Discovery Technologies
      • Genomics-Proteomics
      • Bioinformatics
See more in Biomedtracker

Latest on Metagenomi, Inc.

Scrip

Metagenomi Looks For Upside To Moderna’s Exit

 
• By Andrew McConaghie

Moderna has walked away from an alliance with Metagenomi that could have been worth up to $4bn, returning exclusive rights to its gene-editing technologies and preclinical pipeline. Moderna’s withd

Scrip

IPO Gives Kyverna Cash To Maintain Lead In Autoimmune CAR-T Development

 
• By Mandy Jackson

Kyverna Therapeutics Inc. took advantage of the growing excitement for chimeric antigen receptor T-cell (CAR-T) therapies in the treatment of autoimmune diseases by raising $319m in an initial public

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

 
• By Andrew McConaghie

Scribe Therapeutics is one of a new generation of CRISPR-based gene-editing companies, and believes its in vivo CRISPR X-Editing (XE) technology could be the most efficient yet. Co-founded by CRISP

Scrip

Finance Watch: Kyverna, Alto Offerings Could Land In IPO Investors’ Sweet Spot

 
• By Mandy Jackson

At least five biopharma companies have filed paperwork with the US Securities and Exchange Commission (SEC) since the start of 2024 to signal their intention to go public this year, entering what stil